Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973630 · ClinicalTrials.gov registry record · Phase 1
ATA-200 Gene Therapy Trial in Patients With LGMDR5
A Phase 1 study of LGMD2C, sponsored by Atamyo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05973630: Active Phase 1 study of LGMD2C, sponsored by Atamyo Therapeutics.
NCT05973630 is a Phase 1 study of LGMD2C that is active but no longer recruiting, run by Atamyo Therapeutics. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05973630, a Phase 1 study of LGMD2C, is active but no longer recruiting, sponsored by Atamyo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5).
Primary Outcome
Collection of adverse events at each visit
Conditions Studied
Interventions
- BIOLOGICAL ATA-200
Study Locations (1)
Florida
- Child Health Research Institute - Gainsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2031-01-31 |
| Phase | Phase 1 |
What the registry record for NCT05973630 still lists
NCT05973630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with LGMD2C appearing as the primary indexed condition, and to 1 intervention - of which ATA-200 is the first listed.
NCT05973630 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05973630 about?
NCT05973630 is a clinical study titled "ATA-200 Gene Therapy Trial in Patients With LGMDR5". The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5).
What is the current status of trial NCT05973630?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2025-02-15. Estimated completion is 2031-01-31.
What conditions does trial NCT05973630 study?
This clinical trial studies the following conditions: LGMD2C.
What interventions are being tested in trial NCT05973630?
The interventions under investigation include: ATA-200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05973630?
This trial is sponsored by Atamyo Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973630 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for LGMD2C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05973630's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI